Q-omics provides the consensus-scored KCTD19 profile across patient tissues and cancer cell-line models. KCTD19 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KCTD19 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KCTD19 RNA expression shows 19,694 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where KCTD19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD19 survival associations across molecular data types. KCTD19 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD19 RNA expression–survival associations across cancer types. High KCTD19 expression shows unfavorable associations in ACC and LGG, but favorable associations in UCS, HNSC, PAAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KCTD19 RNA expression.
This table summarizes KCTD19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD19 shows lower tumor expression in KICH and LUAD and higher tumor expression in KIRC, KIRP, COAD and STAD. The KIRC box plot shows higher KCTD19 RNA expression in tumor versus normal tissue (log2 FC = +0.124, t-test p < 0.001).
This table shows molecular features associated with KCTD19 in patient tissues and cancer cell lines. In patient samples, KCTD19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
